-
In a trial of two platinum-based chemotherapy regimens for non-small-cell lung cancer in older patients, pretreatment assessment of physical function and quality of life predicted certain different adverse outcomes but neither treatment assignment was superior to the other with regard to improved "global" quality of life.
-
The primary objective of this prospective cohort study was to evaluate the malignant potential of ultrasound-detected ovarian inclusion cysts in the development of ovarian cancer in menopausal women participating in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) study.
-
The objective of the nichd-funded endo study was to estimate the incidence of endometriosis. The investigators used a matched-exposure cohort design to delineate the burden of endometriosis among women scheduled for surgical care and in the general population from the catchment areas of several surgical centers in the Salt Lake City and San Francisco areas. All subjects in both groups were currently menstruating women aged 1844 years without a prior surgical diagnosis of endometriosis.
-
Over the last 30 years, recommendations regarding weight gain and exercise in pregnancy have been inconsistent. With obesity rates skyrocketing, it is important to encourage pregnant women to be active and to set expectations for pregnancy weight gain at the first prenatal visit.
-
-
In this case-control study, a well-established data-base of patients with interstitial cystitis/painful bladder syndrome (IC/PBS) was used to identify women with nocturia.
-
In this issue: Apixaban could soon join the anticoagulation market; Chinese herbs for flu; chronic medication and discontinuation after hospitalization; and FDA actions.
-
ACEI/ARB therapy for AS; safety alert issued for dronedarone; statins and cancer risk; nesiritide and heart failure; and FDA actions.
-
In a multicenter randomized (not blinded) Phase 3 study of erlotinib vs chemotherapy for EGFR-mutation positive non-small cell lung cancer (NSCLC), progression-free survival was both significantly greater and toxicity less for patients treated with erlotinib. The findings suggest that erlotinib should be considered first-line therapy for patients with advanced EGFR mutation-positive NSCLC.
-
In a case-control study, patients with prostate cancer and matched controls were asked to recall whether they experienced male-pattern baldness by 20, 30, or 40 years of age. Prostate cancer patients were twice as likely to have alopecia at age 20 than controls. Early-age alopecia was not associated with early diagnosis of prostate cancer or with markers of disease aggressiveness. Thus, men with male-pattern baldness at age 20 may be at higher risk for the development of prostate cancer and perhaps more aggressive screening or other disease preventing interventions might prove beneficial for this population.
